All NAD+ certificates

NAD+ 500 mg Certificate of Analysis Batch APL-NAD500-2608-03

NAD+ 500 mg from batch APL-NAD500-2608-03 was analysed on 17 August 2026 and measured 99.29% purity by HPLC / Mass Spectrometry, passing all 5 release tests.

Purity
99.29%
Result
All 5 tests passed
Tested
17 August 2026
Method
HPLC / Mass Spectrometry
Net content
503.1 mg

Independent verification

NAD+ 500 mg is independently tested for bacterial endotoxin by Ozcanium Analytics, an independent Australian laboratory: below 15.0 EU per vial by kinetic chromogenic LAL, analysed 30 August 2026 on lot APL-NAD500-2608-01, verification code OZ-ENDOTX-TAU3.

Issued by Ozcanium Analytics. Covers every vial size of this compound; each report opens as the laboratory issued it.

Enter a code in the Ozcanium Analytics verification portal (opens in a new tab) to confirm the report against their own records.

The certificate as issued is reproduced below — pinch to zoom on a phone, or use Print / Save as PDF for a full-size copy.

Australian Peptide Labs

In-House Analytical Laboratory

Australian Peptide Labs Pty Ltd

ABN 55 696 074 361

australianpeptidelabs.com.au

Page 1 of 2

Certificate of Analysis NAD+ 500 mg Batch APL-NAD500-2608-03
Compound
NAD+
Lot Number
APL-NAD500-2608-03
Analysis Date
17 August 2026
Method
HPLC / Mass Spectrometry
Purity
99.29%
Net Content
503.1 mg
NAD+ vial
CAS Number
53-84-9
Formula
C21H27N7O14P2
Molecular Weight
663.43 g/mol
Form
Lyophilised Powder
Manufactured
August 2026
Issued
18 August 2026
Document ID
APL-COA-NAD500-2608-03
Verification Code
Batch traceable

High Performance Liquid Chromatography (HPLC-UV) Chromatogram

mAUPDA 214 nm025050075010000.50.811.31.51.822.32.5 min 0.9601.180NAD+1.4902.120

Main peak integrated at 99.29% of total area; no single impurity peak exceeds 0.31%.

Peak List

Peaks detected: 4
#Time (min)Area% AreaIdentification
10.96015,8400.220—
21.1807,148,88099.290NAD+
31.49022,3200.310—
42.12012,9600.180—

Analytical Results

TestSpecificationResultStatus
AppearanceWhite/Off-White Lyophilised PowderConformsPASS
Identity (MS)ConfirmedConfirmedPASS
Purity (HPLC)≥98.0%99.29%PASS
Assay (HPLC)98.0–102.0%99.4%PASS
Endotoxins<0.5 EU/mg<0.20 EU/mgPASS

Australian Peptide Labs

In-House Analytical Laboratory

Australian Peptide Labs Pty Ltd

ABN 55 696 074 361

australianpeptidelabs.com.au

Page 2 of 2

NAD+ 500 mg

CAS Number: 53-84-9

Liquid Chromatography Mass Spectrometry (LC-MS) Identity Analysis

Identity confirmation with SIM

Analysis date: 17 August 2026
Monitored (m/z)Detected (m/z)Relative Intensity
664664.442.6
686686.421.1

Detection assignment: NAD+

Collected Mass Spectrum

Intensity ×107

01233004005006007008009001000 m/z 664686

Verification Protocol

  • Identity confirmed by mass spectrometry against the expected ion channels.
  • Purity measured by HPLC as peak area against all integrated impurity peaks.
  • Batch traceability: this document reports the lot number printed on the vial.
  • Analysis performed in-house by Australian Peptide Labs.

Supplied for laboratory research use only. Not a therapeutic good; not for human or veterinary use.

View NAD+ in the catalogueHow to read this certificate